Skip to main content

Table 1 Descriptive analysis of different DAA treatment regimens received by patients in group I

From: Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma recurrence

HCV treatmentNumberPercent
SOF/DAC12.0
SOF/DAC/RBV3060.0
SOF/LED510.0
SOF/LED/RBV12.0
SOF/RBV918.0
SOF/SIM48.0
HCV treatment (weeks)
 Min.–Max.12.0–24.0
 Mean ± SD14.64 ± 5.02
 Median12.0
PCR after TTT
 SVR4284.0
 Relapser816.0
  1. SOF sofosbuvir, LED ledipasvir, RBV ribavirin, SIM simeprevir, DAC daclatasvir, PCR polymerase chain reaction, SVR sustained virological response